NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Pacira Biosciences, Inc. PCRX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$726.4M
▲ 3.6% vs FY2024
EPS · FY25
$0.16
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
1.0%
Net margin · FY25
1.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 726.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 0.16
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
1.0%
Return on equity, FY2025
ROE
Operating margin2.6%
Net margin1.0%
Return on assets0.5%
Each USD of equity produced 1 cents of profit this year.
Returned to shareholders
USD 147.8M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 147.8M
Share of profit2101.6%
Consecutive raises—
USD 147.8M in buybacks — 2102% of the year's profit, so the payout drew on cash built up earlier.
Growth
+11.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.9%
+11.1%
+11.3%
+29.8%
Net income
−23.8%
−45.4%
+14.3%
EPS, diluted
−22.2%
−45.5%
+14.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years−5.8%
Change, 10 years+11.6%
The share count shrank 6% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.3B
total assets, end of FY2025
Total assetsUSD 1.3B
EquityUSD 693.1M
CashUSD 158.5M
Gross debtUSD 372.2M
Net debtUSD 213.6M
Current ratio4.54×
Net debt stands at 31% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.7
0.7
0.7
0.7
0.5
0.4
0.4
0.3
0.3
0.3
0.2
0.2
0.1
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.1
0.1
0.1
0.1
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.1
0.0
0.2
0.2
0.1
0.1
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
0.0
−0.1
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
·
·
Net income $B
0.0
−0.1
0.0
0.0
0.0
0.1
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
0.16
−2.15
0.89
0.34
0.92
3.33
−0.27
−0.01
−1.07
−1.02
0.04
−0.39
−1.93
−1.72
−2.64
−47.29
−55.32
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
1.0
−12.1
5.1
2.1
6.2
29.9
−3.3
−0.2
−17.1
−17.4
1.0
−12.9
−119.3
−91.6
·
·
·
Shares out B
0.04
0.05
0.05
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed